Achieve Life Sciences, Inc. (ACHV) Financial Analysis & Valuation | Quarter Chart
Achieve Life Sciences, Inc. (ACHV)
ACHVPrice: $4.17
Fair Value: 🔒
🔒score
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine ... more
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of... more
Description
Shares
| Market Cap | $221.99M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | CA | CEO | Richard A. Stewart |
| IPO Date | 1995-10-12 | CAGR | — |
| Employees | 25 | Website | www.achievelifesciences.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ACHV chart loading...
Fundamentals
Technicals
| Enterprise Value | $118.48M | P/E Ratio | -3.09 |
| Forward P/E | -4.43 | PEG Ratio | — |
| P/S Ratio | 71.53 | P/B Ratio | 0.48 |
| P/CF Ratio | -0.4 | P/FCF Ratio | -0.4 |
| EPS | $-1.35 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | -0.01% |
| Operating Margin | -165.12% | Profit Margin | -229.59% |
| ROE | -1.97% | ROA | -1.01% |
| ROCE | -0.89% | Current Ratio | 5.14 |
| Quick Ratio | 5.14 | Cash Ratio | 3.28 |
| Debt/Equity | 0.3 | Interest Coverage | -98.81 |
| Altman Z Score | -0.81 | Piotroski Score | 3 |